Trial Outcomes & Findings for Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities (NCT NCT02137785)

NCT ID: NCT02137785

Last Updated: 2015-09-16

Results Overview

proportion of subjects in each treatment group with a count of zero lesions in the Treatment Area

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

269 participants

Primary outcome timeframe

Week 12

Results posted on

2015-09-16

Participant Flow

Participant milestones

Participant milestones
Measure
ALA-PDT
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Overall Study
STARTED
135
134
Overall Study
COMPLETED
132
130
Overall Study
NOT COMPLETED
3
4

Reasons for withdrawal

Reasons for withdrawal
Measure
ALA-PDT
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Overall Study
Lost to Follow-up
1
0
Overall Study
Withdrawal by Subject
1
4
Overall Study
subject moved out of state
1
0

Baseline Characteristics

Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Total
n=269 Participants
Total of all reporting groups
Skin Type
Type I
17 participants
n=5 Participants
16 participants
n=7 Participants
33 participants
n=5 Participants
Skin Type
Type II
67 participants
n=5 Participants
73 participants
n=7 Participants
140 participants
n=5 Participants
Skin Type
Type III
37 participants
n=5 Participants
32 participants
n=7 Participants
69 participants
n=5 Participants
Skin Type
Type IV
14 participants
n=5 Participants
13 participants
n=7 Participants
27 participants
n=5 Participants
Skin Type
Type V
0 participants
n=5 Participants
0 participants
n=7 Participants
0 participants
n=5 Participants
Skin Type
Type VI
0 participants
n=5 Participants
0 participants
n=7 Participants
0 participants
n=5 Participants
Total Number AK Lesions (Grade 1/2)
8.5 lesions per subject
STANDARD_DEVIATION 3.6 • n=5 Participants
8.6 lesions per subject
STANDARD_DEVIATION 3.4 • n=7 Participants
8.5 lesions per subject
STANDARD_DEVIATION 3.5 • n=5 Participants
Age, Continuous
67.6 years
n=5 Participants
67.6 years
n=7 Participants
67.6 years
n=5 Participants
Sex: Female, Male
Female
43 Participants
n=5 Participants
38 Participants
n=7 Participants
81 Participants
n=5 Participants
Sex: Female, Male
Male
92 Participants
n=5 Participants
96 Participants
n=7 Participants
188 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=5 Participants
3 Participants
n=7 Participants
3 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
135 Participants
n=5 Participants
131 Participants
n=7 Participants
266 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
White
135 Participants
n=5 Participants
134 Participants
n=7 Participants
269 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Week 12

Population: ITT

proportion of subjects in each treatment group with a count of zero lesions in the Treatment Area

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Complete Clearance Rate
42 participants
17 participants

SECONDARY outcome

Timeframe: Baseline and Week 12

Population: ITT using observed data only

{1 - \[(number of AK lesions at follow-up)/(number of AK lesions at Baseline)\]} x 100

Outcome measures

Outcome measures
Measure
ALA-PDT
n=132 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=130 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
AK Clearance Rate
69.1 percentage of baseline lesions cleared
Standard Deviation 37.4
29.9 percentage of baseline lesions cleared
Standard Deviation 51.5

SECONDARY outcome

Timeframe: Baseline and Week 8

Population: ITT using observed data only

{1 - \[(number of AK lesions at follow-up)/(number of AK lesions at Baseline)\]} x 100

Outcome measures

Outcome measures
Measure
ALA-PDT
n=133 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=129 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
AK Clearance Rate
53.4 percentage of baseline lesions cleared
Standard Deviation 45.0
26.3 percentage of baseline lesions cleared
Standard Deviation 44.3

SECONDARY outcome

Timeframe: Week 8

Population: ITT

proportion of subjects in each treatment group with a count of zero lesions in the Treatment Area

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Complete Clearance Rate
35 participants
12 participants

SECONDARY outcome

Timeframe: Week 12

Population: ITT

Subject satisfaction score 1. = Excellent (very satisfied) 2. = Good (moderately satisfied) 3. = Fair (slightly satisfied) 4. = Poor (not satisfied at all)

Outcome measures

Outcome measures
Measure
ALA-PDT
n=134 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=131 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Subject Satisfaction Score
Very Satisfied
71 participants
29 participants
Subject Satisfaction Score
Moderately Satisfied
47 participants
26 participants
Subject Satisfaction Score
Slightly Satisfied
12 participants
28 participants
Subject Satisfaction Score
Not Satisfied
4 participants
48 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline

Population: ITT

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Hyperpigmentation
Grade 0 (none)
46 participants
53 participants
Hyperpigmentation
Grade 1 (light)
51 participants
34 participants
Hyperpigmentation
Grade 2 (moderate - small)
27 participants
35 participants
Hyperpigmentation
Grade 3 (moderate - moderate)
10 participants
10 participants
Hyperpigmentation
Grade 4 (marked)
1 participants
2 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 24-48 hours after PDT #1

Population: ITT

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Hyperpigmentation
Grade 0 (none)
46 participants
58 participants
Hyperpigmentation
Grade 1 (light)
49 participants
34 participants
Hyperpigmentation
Grade 2 (moderate - small)
28 participants
30 participants
Hyperpigmentation
Grade 3 (moderate - moderate)
11 participants
10 participants
Hyperpigmentation
Grade 4 (marked)
1 participants
2 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 2 Weeks after PDT #1

Population: ITT

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Hyperpigmentation
Grade 0 (none)
45 participants
58 participants
Hyperpigmentation
Grade 1 (light)
46 participants
35 participants
Hyperpigmentation
Grade 2 (moderate - small)
33 participants
30 participants
Hyperpigmentation
Grade 3 (moderate - moderate)
10 participants
9 participants
Hyperpigmentation
Grade 4 (marked)
1 participants
2 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 4 Weeks after PDT #1

Population: ITT

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=132 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Hyperpigmentation
Grade 1 (light)
44 participants
37 participants
Hyperpigmentation
Grade 0 (none)
51 participants
56 participants
Hyperpigmentation
Grade 2 (moderate - small)
30 participants
28 participants
Hyperpigmentation
Grade 3 (moderate - moderate)
9 participants
9 participants
Hyperpigmentation
Grade 4 (marked)
1 participants
2 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 8 Weeks after PDT #1

Population: ITT

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Outcome measures

Outcome measures
Measure
ALA-PDT
n=132 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=129 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Hyperpigmentation
Grade 4 (marked)
1 participants
2 participants
Hyperpigmentation
Grade 0 (none)
51 participants
53 participants
Hyperpigmentation
Grade 1 (light)
44 participants
37 participants
Hyperpigmentation
Grade 2 (moderate - small)
27 participants
27 participants
Hyperpigmentation
Grade 3 (moderate - moderate)
9 participants
10 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 12 Weeks after PDT #1

Population: ITT

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Outcome measures

Outcome measures
Measure
ALA-PDT
n=132 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=130 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Hyperpigmentation
Grade 1 (light)
42 participants
43 participants
Hyperpigmentation
Grade 2 (moderate - small)
29 participants
26 participants
Hyperpigmentation
Grade 0 (none)
52 participants
49 participants
Hyperpigmentation
Grade 3 (moderate - moderate)
8 participants
10 participants
Hyperpigmentation
Grade 4 (marked)
1 participants
2 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline

Population: ITT

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation Grade 4 = Marked hypopigmentation involving moderate or large sized areas

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Hypopigmentation
Grade 0 (none)
75 participants
64 participants
Hypopigmentation
Grade 1 (light)
40 participants
47 participants
Hypopigmentation
Grade 2 (moderate - small)
16 participants
17 participants
Hypopigmentation
Grade 3 (moderate - moderate)
4 participants
4 participants
Hypopigmentation
Grade 4 (marked)
0 participants
2 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 24-48 hours after PDT #1

Population: ITT

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation Grade 4 = Marked hypopigmentation involving moderate or large sized areas

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Hypopigmentation
Grade 0 (none)
76 participants
68 participants
Hypopigmentation
Grade 1 (light)
42 participants
46 participants
Hypopigmentation
Grade 2 (moderate - small)
12 participants
14 participants
Hypopigmentation
Grade 3 (moderate - moderate)
5 participants
4 participants
Hypopigmentation
Grade 4 (marked)
0 participants
2 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 2 Weeks after PDT #1

Population: ITT

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation Grade 4 = Marked hypopigmentation involving moderate or large sized areas

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Hypopigmentation
Grade 0 (none)
74 participants
67 participants
Hypopigmentation
Grade 1 (light)
44 participants
47 participants
Hypopigmentation
Grade 2 (moderate - small)
13 participants
14 participants
Hypopigmentation
Grade 3 (moderate - moderate)
4 participants
4 participants
Hypopigmentation
Grade 4 (marked)
0 participants
2 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 4 Weeks after PDT #1

Population: ITT

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation Grade 4 = Marked hypopigmentation involving moderate or large sized areas

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=132 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Hypopigmentation
Grade 0 (none)
76 participants
65 participants
Hypopigmentation
Grade 1 (light)
42 participants
47 participants
Hypopigmentation
Grade 2 (moderate - small)
13 participants
14 participants
Hypopigmentation
Grade 3 (moderate - moderate)
4 participants
4 participants
Hypopigmentation
Grade 4 (marked)
0 participants
2 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 8 Weeks after PDT #1

Population: ITT

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation Grade 4 = Marked hypopigmentation involving moderate or large sized areas

Outcome measures

Outcome measures
Measure
ALA-PDT
n=132 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=129 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Hypopigmentation
Grade 0 (none)
75 participants
63 participants
Hypopigmentation
Grade 1 (light)
39 participants
45 participants
Hypopigmentation
Grade 2 (moderate - small)
15 participants
15 participants
Hypopigmentation
Grade 3 (moderate - moderate)
3 participants
4 participants
Hypopigmentation
Grade 4 (marked)
0 participants
2 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 12 Weeks after PDT #1

Population: ITT

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation Grade 4 = Marked hypopigmentation involving moderate or large sized areas

Outcome measures

Outcome measures
Measure
ALA-PDT
n=132 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=130 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Hypopigmentation
Grade 0 (none)
73 participants
66 participants
Hypopigmentation
Grade 1 (light)
40 participants
45 participants
Hypopigmentation
Grade 2 (moderate - small)
16 participants
14 participants
Hypopigmentation
Grade 3 (moderate - moderate)
3 participants
3 participants
Hypopigmentation
Grade 4 (marked)
0 participants
2 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline

Population: ITT

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Erythema
Grade 0 (none)
73 participants
73 participants
Erythema
Grade 2 (mild)
21 participants
19 participants
Erythema
Grade 4 (severe)
0 participants
0 participants
Erythema
Grade 1 (minimal)
38 participants
39 participants
Erythema
Grade 3 (moderate)
3 participants
3 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 5 minutes after PDT #1

Population: ITT

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Erythema
Grade 0 (none)
12 participants
57 participants
Erythema
Grade 1 (light)
26 participants
41 participants
Erythema
Grade 2 (mild)
43 participants
27 participants
Erythema
Grade 3 (moderate)
52 participants
9 participants
Erythema
Grade 4 (severe)
2 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 24-48 hours after PDT #1

Population: ITT

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Erythema
Grade 0 (none)
2 participants
64 participants
Erythema
Grade 1 (minimal)
16 participants
43 participants
Erythema
Grade 2 (mild)
48 participants
23 participants
Erythema
Grade 3 (moderate)
66 participants
4 participants
Erythema
Grade 4 (severe)
3 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 2 Weeks after PDT #1

Population: ITT

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Erythema
Grade 0 (none)
28 participants
61 participants
Erythema
Grade 1 (minimal)
46 participants
58 participants
Erythema
Grade 2 (mild)
51 participants
14 participants
Erythema
Grade 3 (moderate)
10 participants
1 participants
Erythema
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 4 Weeks after PDT #1

Population: ITT

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=132 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Erythema
Grade 0 (none)
54 participants
72 participants
Erythema
Grade 1 (minimal)
54 participants
49 participants
Erythema
Grade 2 (mild)
24 participants
11 participants
Erythema
Grade 3 (moderate)
3 participants
0 participants
Erythema
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 8 Weeks after PDT #1

Population: ITT

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Outcome measures

Outcome measures
Measure
ALA-PDT
n=132 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=129 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Erythema
Grade 0 (none)
79 participants
81 participants
Erythema
Grade 1 (minimal)
30 participants
39 participants
Erythema
Grade 2 (mild)
18 participants
7 participants
Erythema
Grade 3 (moderate)
5 participants
2 participants
Erythema
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 12 Weeks after PDT #1

Population: ITT

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Outcome measures

Outcome measures
Measure
ALA-PDT
n=132 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=130 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Erythema
Grade 0 (none)
80 participants
85 participants
Erythema
Grade 1 (minimal)
34 participants
36 participants
Erythema
Grade 2 (mild)
15 participants
8 participants
Erythema
Grade 3 (moderate)
3 participants
1 participants
Erythema
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline

Population: ITT

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Edema
Grade 0 (none)
133 participants
134 participants
Edema
Grade 1 (minimal)
2 participants
0 participants
Edema
Grade 2 (mild)
0 participants
0 participants
Edema
Grade 3 (moderate)
0 participants
0 participants
Edema
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 5 minutes after PDT #1

Population: ITT

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Edema
Grade 0 (none)
92 participants
127 participants
Edema
Grade 1 (minimal)
30 participants
7 participants
Edema
Grade 2 (mild)
10 participants
0 participants
Edema
Grade 3 (moderate)
3 participants
0 participants
Edema
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 24-48 hours after PDT #1

Population: ITT

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Edema
Grade 0 (none)
89 participants
133 participants
Edema
Grade 1 (minimal)
27 participants
0 participants
Edema
Grade 2 (mild)
18 participants
1 participants
Edema
Grade 3 (moderate)
1 participants
0 participants
Edema
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 2 weeks after PDT #1

Population: ITT

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Edema
Grade 0 (none)
131 participants
134 participants
Edema
Grade 1 (minimal)
4 participants
0 participants
Edema
Grade 2 (mild)
0 participants
0 participants
Edema
Grade 3 (moderate)
0 participants
0 participants
Edema
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 4 Weeks after PDT #1

Population: ITT

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=132 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Edema
Grade 0 (none)
134 participants
132 participants
Edema
Grade 1 (minimal)
1 participants
0 participants
Edema
Grade 2 (mild)
0 participants
0 participants
Edema
Grade 3 (moderate)
0 participants
0 participants
Edema
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 8 Weeks after PDT #1

Population: ITT

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Outcome measures

Outcome measures
Measure
ALA-PDT
n=132 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=129 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Edema
Grade 0 (none)
131 participants
128 participants
Edema
Grade 1 (minimal)
0 participants
0 participants
Edema
Grade 2 (mild)
1 participants
0 participants
Edema
Grade 3 (moderate)
0 participants
1 participants
Edema
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 12 Weeks after PDT #1

Population: ITT

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Outcome measures

Outcome measures
Measure
ALA-PDT
n=132 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=130 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Edema
Grade 0 (none)
132 participants
130 participants
Edema
Grade 1 (minimal)
0 participants
0 participants
Edema
Grade 2 (mild)
0 participants
0 participants
Edema
Grade 3 (moderate)
0 participants
0 participants
Edema
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline

Population: ITT

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Stinging/Burning
Grade 0 (none)
134 participants
133 participants
Stinging/Burning
Grade 1 (mild)
1 participants
0 participants
Stinging/Burning
Grade 2 (moderate)
0 participants
1 participants
Stinging/Burning
Grade 3 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: During PDT #1

Population: ITT

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Stinging/Burning
Grade 0 (none)
10 participants
111 participants
Stinging/Burning
Grade 1 (mild)
39 participants
23 participants
Stinging/Burning
Grade 2 (moderate)
74 participants
0 participants
Stinging/Burning
Grade 3 (severe)
12 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 5 minutes after PDT #1

Population: ITT

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Stinging/Burning
Grade 0 (none)
30 participants
130 participants
Stinging/Burning
Grade 1 (mild)
70 participants
4 participants
Stinging/Burning
Grade 2 (moderate)
35 participants
0 participants
Stinging/Burning
Grade 3 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 24-48 Hours after PDT #1

Population: ITT

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Stinging/Burning
Grade 0 (none)
107 participants
132 participants
Stinging/Burning
Grade 1 (mild)
23 participants
2 participants
Stinging/Burning
Grade 2 (moderate)
5 participants
0 participants
Stinging/Burning
Grade 3 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 2 Weeks after PDT #1

Population: ITT

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Stinging/Burning
Grade 0 (none)
131 ITT
134 ITT
Stinging/Burning
Grade 1 (mild)
3 ITT
0 ITT
Stinging/Burning
Grade 2 (moderate)
0 ITT
0 ITT
Stinging/Burning
Grade 3 (severe)
1 ITT
0 ITT

OTHER_PRE_SPECIFIED outcome

Timeframe: 4 Weeks after PDT #1

Population: ITT

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=132 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Stinging/Burning
Grade 0 (none)
132 participants
132 participants
Stinging/Burning
Grade 1 (mild)
2 participants
0 participants
Stinging/Burning
Grade 2 (moderate)
1 participants
0 participants
Stinging/Burning
Grade 3 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 8 Weeks after PDT #1

Population: ITT

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Outcome measures

Outcome measures
Measure
ALA-PDT
n=132 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=129 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Stinging/Burning
Grade 0 (none)
130 participants
129 participants
Stinging/Burning
Grade 1 (mild)
2 participants
0 participants
Stinging/Burning
Grade 2 (moderate)
0 participants
0 participants
Stinging/Burning
Grade 3 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 12 Weeks after PDT #1

Population: ITT

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Outcome measures

Outcome measures
Measure
ALA-PDT
n=132 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=130 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Stinging/Burning
Grade 0 (none)
130 participants
130 participants
Stinging/Burning
Grade 1 (mild)
1 participants
0 participants
Stinging/Burning
Grade 2 (moderate)
1 participants
0 participants
Stinging/Burning
Grade 3 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline

Population: ITT

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Scaling & Dryness
Grade 0 (none)
83 participants
78 participants
Scaling & Dryness
Grade 1 (minimal)
35 participants
41 participants
Scaling & Dryness
Grade 2 (mild)
10 participants
11 participants
Scaling & Dryness
Grade 3 (moderate)
7 participants
4 participants
Scaling & Dryness
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 24-48 hours after PDT #1

Population: ITT

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Scaling & Dryness
Grade 0 (none)
84 participants
79 participants
Scaling & Dryness
Grade 1 (minimal)
30 participants
40 participants
Scaling & Dryness
Grade 2 (mild)
17 participants
10 participants
Scaling & Dryness
Grade 3 (moderate)
4 participants
5 participants
Scaling & Dryness
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 2 Weeks after PDT #1

Population: ITT

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Scaling & Dryness
Grade 0 (none)
33 participants
81 participants
Scaling & Dryness
Grade 1 (minimal)
47 participants
38 participants
Scaling & Dryness
Grade 2 (mild)
29 participants
11 participants
Scaling & Dryness
Grade 3 (moderate)
26 participants
4 participants
Scaling & Dryness
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 4 Weeks after PDT #1

Population: ITT

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=132 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Scaling & Dryness
Grade 0 (none)
73 participants
83 participants
Scaling & Dryness
Grade 1 (minimal)
44 participants
38 participants
Scaling & Dryness
Grade 2 (mild)
15 participants
11 participants
Scaling & Dryness
Grade 3 (moderate)
3 participants
0 participants
Scaling & Dryness
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 8 Weeks after PDT #1

Population: ITT

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Outcome measures

Outcome measures
Measure
ALA-PDT
n=132 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=129 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Scaling & Dryness
Grade 0 (none)
83 participants
86 participants
Scaling & Dryness
Grade 1 (minimal)
35 participants
35 participants
Scaling & Dryness
Grade 2 (mild)
11 participants
5 participants
Scaling & Dryness
Grade 3 (moderate)
3 participants
3 participants
Scaling & Dryness
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 12 Weeks after PDT #1

Population: ITT

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Outcome measures

Outcome measures
Measure
ALA-PDT
n=132 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=130 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Scaling & Dryness
Grade 0 (none)
85 participants
86 participants
Scaling & Dryness
Grade 1 (minimal)
33 participants
32 participants
Scaling & Dryness
Grade 2 (mild)
9 participants
10 participants
Scaling & Dryness
Grade 3 (moderate)
5 participants
2 participants
Scaling & Dryness
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline

Population: ITT

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Oozing/Vesiculation/Crusting
Grade 0 (none)
128 participants
129 participants
Oozing/Vesiculation/Crusting
Grade 1 (minimal)
7 participants
4 participants
Oozing/Vesiculation/Crusting
Grade 2 (mild)
0 participants
1 participants
Oozing/Vesiculation/Crusting
Grade 3 (moderate)
0 participants
0 participants
Oozing/Vesiculation/Crusting
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 24-48 hours after PDT #1

Population: ITT

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Oozing/Vesiculation/Crusting
Grade 0 (none)
116 participants
127 participants
Oozing/Vesiculation/Crusting
Grade 1 (minimal)
12 participants
3 participants
Oozing/Vesiculation/Crusting
Grade 2 (mild)
5 participants
3 participants
Oozing/Vesiculation/Crusting
Grade 3 (moderate)
2 participants
1 participants
Oozing/Vesiculation/Crusting
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 2 Weeks after PDT #1

Population: ITT

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Oozing/Vesiculation/Crusting
Grade 0 (none)
92 participants
129 participants
Oozing/Vesiculation/Crusting
Grade 1 (minimal)
23 participants
4 participants
Oozing/Vesiculation/Crusting
Grade 2 (mild)
16 participants
1 participants
Oozing/Vesiculation/Crusting
Grade 3 (moderate)
4 participants
0 participants
Oozing/Vesiculation/Crusting
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 4 Weeks after PDT #1

Population: ITT

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Outcome measures

Outcome measures
Measure
ALA-PDT
n=135 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=132 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Oozing/Vesiculation/Crusting
Grade 0 (none)
121 participants
129 participants
Oozing/Vesiculation/Crusting
Grade 1 (minimal)
12 participants
2 participants
Oozing/Vesiculation/Crusting
Grade 2 (mild)
2 participants
1 participants
Oozing/Vesiculation/Crusting
Grade 3 (moderate)
0 participants
0 participants
Oozing/Vesiculation/Crusting
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 8 Weeks after PDT #1

Population: ITT

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Outcome measures

Outcome measures
Measure
ALA-PDT
n=132 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=129 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Oozing/Vesiculation/Crusting
Grade 0 (none)
125 participants
124 participants
Oozing/Vesiculation/Crusting
Grade 1 (minimal)
5 participants
3 participants
Oozing/Vesiculation/Crusting
Grade 2 (mild)
2 participants
2 participants
Oozing/Vesiculation/Crusting
Grade 3 (moderate)
0 participants
0 participants
Oozing/Vesiculation/Crusting
Grade 4 (severe)
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 12 Weeks after PDT #1

Population: ITT

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Outcome measures

Outcome measures
Measure
ALA-PDT
n=132 Participants
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=130 Participants
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Oozing/Vesiculation/Crusting
Grade 0 (none)
123 participants
125 participants
Oozing/Vesiculation/Crusting
Grade 1 (minimal)
5 participants
4 participants
Oozing/Vesiculation/Crusting
Grade 2 (mild)
3 participants
0 participants
Oozing/Vesiculation/Crusting
Grade 3 (moderate)
1 participants
1 participants
Oozing/Vesiculation/Crusting
Grade 4 (severe)
0 participants
0 participants

Adverse Events

ALA-PDT

Serious events: 5 serious events
Other events: 6 other events
Deaths: 0 deaths

Vehicle

Serious events: 2 serious events
Other events: 6 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
ALA-PDT
n=135 participants at risk
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 participants at risk
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Cardiac disorders
Angina Unstable
0.74%
1/135 • Number of events 1 • 3 months
0.00%
0/134 • 3 months
Blood and lymphatic system disorders
Iron Deficiency Anaemia
0.00%
0/135 • 3 months
0.75%
1/134 • Number of events 1 • 3 months
Cardiac disorders
Atrial Fibrillation
0.74%
1/135 • Number of events 1 • 3 months
0.00%
0/134 • 3 months
Cardiac disorders
Chest Pressure
0.74%
1/135 • Number of events 1 • 3 months
0.00%
0/134 • 3 months
Gastrointestinal disorders
Pancreatitis
0.00%
0/135 • 3 months
0.75%
1/134 • Number of events 1 • 3 months
Infections and infestations
Appendicitis
0.74%
1/135 • Number of events 1 • 3 months
0.00%
0/134 • 3 months
Nervous system disorders
Dizziness
0.74%
1/135 • Number of events 1 • 3 months
0.00%
0/134 • 3 months
Nervous system disorders
Syncope
0.74%
1/135 • Number of events 1 • 3 months
0.00%
0/134 • 3 months
Renal and urinary disorders
Renal Failure Acute
0.74%
1/135 • Number of events 1 • 3 months
0.00%
0/134 • 3 months
Respiratory, thoracic and mediastinal disorders
Dyspnoea
1.5%
2/135 • Number of events 4 • 3 months
0.00%
0/134 • 3 months
Respiratory, thoracic and mediastinal disorders
Hypoxia
0.74%
1/135 • Number of events 1 • 3 months
0.00%
0/134 • 3 months

Other adverse events

Other adverse events
Measure
ALA-PDT
n=135 participants at risk
Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Vehicle
n=134 participants at risk
Topical Solution Vehicle: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light BLU-U Blue Light Photodynamic Therapy Illuminator: 10 J/cm2 blue light delivered at 10mW/cm2
Infections and infestations
Nasopharyngitis
1.5%
2/135 • 3 months
3.0%
4/134 • 3 months
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous Cell Carcinoma of Skin
3.0%
4/135 • 3 months
1.5%
2/134 • 3 months

Additional Information

Anna Houlihan

DUSA Pharmaceuticals Inc., a Sun Pharma Co.

Phone: 9147608796

Results disclosure agreements

  • Principal investigator is a sponsor employee The first publication of results from multi-center trial will be made by the Sponsor. If publication is not submitted within 12 months after conclusion of the study, the PI may publish the results from the site individually, subject to compliance with the other terms of the clinical trial agreement, including a requirement that the PI provide a draft of the publication for the sponsor's review 30-75 days before submission so that sponsor can review the publication for confidential information.
  • Publication restrictions are in place

Restriction type: OTHER